Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)

Intravenous daratumumab is approved for the treatment of multiple myeloma. In part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of daratumumab with recombinant human hyaluronidase PH20 (rHuPH20) was well tolerated, with low rates of infusion-related reactions and an efficacy simil...

Descripción completa

Detalles Bibliográficos
Autores principales: San-Miguel, Jesus, Usmani, Saad Z., Mateos, Maria-Victoria, van de Donk, Niels W.C.J., Kaufman, Jonathan L., Moreau, Philippe, Oriol, Albert, Plesner, Torben, Benboubker, Lotfi, Liu, Kevin, Hellemans, Peter, Masterson, Tara, Clemens, Pamela L., Luo, Man, Farnsworth, Andrew, Nahi, Hareth, Chari, Ajai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168515/
https://www.ncbi.nlm.nih.gov/pubmed/32354874
http://dx.doi.org/10.3324/haematol.2019.243790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168515/
https://www.ncbi.nlm.nih.gov/pubmed/32354874
http://dx.doi.org/10.3324/haematol.2019.243790

Ejemplares similares